

Quality Improvement (QI) Plan-Do-Study-Act (PDSA)

QI activity focus / Objective		Increasing uptake of RSV Immunisation in pregnant women and babies	
QI activity lead/s		Practice nurse	
Start measure	Number of eligible babies immunised against RSV ____	End measure	Number of eligible babies immunised against RSV ____
	Number of pregnant women immunized against RSV ____		Number of pregnant women immunized against RSV ____
	Number of eligible children entering their second RSV season immunized against RSV ____		Number of eligible children entering their second RSV season immunized against RSV ____
Start date	June 2026	End date	September 2026

<p>Step 1: PLAN</p> <p>What do you plan to do/achieve</p>	<p>Context: Respiratory Syncytial Virus (RSV) poses significant risks, especially for babies and young children, as it can cause severe respiratory illnesses such as bronchiolitis and pneumonia. These conditions may lead to hospitalisation, particularly for infants under six months of age, premature babies, and those with underlying health conditions.</p> <p>Goal: Throughout the 2026 RSV season, which extends from currently until September 2026, our practice would like to increase the number of eligible babies immunised against RSV.</p> <p>This will include:</p> <ul style="list-style-type: none"> • Infants born between 1 April 2026 and 30 September 2026 whose mother did not receive Abrysvo during pregnancy, or received it less than two weeks before giving birth, • Infants born between 1 October 2025 and 31 March 2026. • Aboriginal infants and children born on or after 1 October 2024 entering their second RSV season, • Infants with specific high risk medical conditions (MRC) born on or after 1 October 2024. <p>Notes: Please see RSV Maternal and Infant Immunisation Recall and Reminder Guide in 'Other Information.'</p> <p>Note: If a mother has received Abrysvo, Beyfortus® is not recommended for the infant, unless the infant has a high-risk condition, the mother is immunocompromised or insufficient time (<2 weeks) between Abrysvo and the infants birth has occurred to ensure adequate antibody generation.</p> <p>RSV decision aid</p>
<p>Step 2: DO</p> <p>Outline the steps you will undertake</p>	<p>As the RSV Immunisation program in babies depends on whether the mother received Abrysvo during pregnancy, this activity will involve several searches and collating them due to the separate patient files. However, we expect that for most practices the lists generated will be reasonably small and therefore this process should be manageable.</p> <p>Educate & Inform team of QI Activity</p> <ol style="list-style-type: none"> 1. Ensure staff are educated on RSV immunisation (WA Health has created a RSV immunisation module for immunisation providers - Immunisation education) 2. Educating/ Informing all staff of QI Intentions, goals and impacts <ul style="list-style-type: none"> • Increased recalls - how this may impact Admin phone calls • Increased immunisation appointments – Impact doctor variety of appointments • Increased Equipment (syringes, needles, etc) usage increasing treatment room costs • Increased Vaccination orders needing more cold chain storage

Quality Improvement (QI) Plan-Do-Study-Act (PDSA)

QI activity focus / Objective		Increasing uptake of RSV Immunisation in pregnant women and babies	
QI activity lead/s		Practice nurse	
Start measure	Number of eligible babies immunised against RSV ____	End measure	Number of eligible babies immunised against RSV ____
	Number of pregnant women immunized against RSV ____		Number of pregnant women immunized against RSV ____
	Number of eligible children entering their second RSV season immunized against RSV ____		Number of eligible children entering their second RSV season immunized against RSV ____
Start date	June 2026	End date	September 2026

- Overall increased appointments reducing overall availability of staff involved, resulting in waitlists

Baseline data

3. QI lead to run searches on Best Practice as follows, and export to spreadsheet/ preferred form of list (all SQLs available in 'Other Information section to copy and paste):

List a) Pregnant women over who have not received Abrysvo in the last 12 months.

List b) Women who have had a pregnancy recorded within the last year and have received Abrysvo within the last 12 months.

List c) Babies born after 1/10/2025

List d) Children born after 01/10/2024 who are Aboriginal or Torres Strait Islander or have an eligible Medical Risk Condition (MRC).

How to save as CSV file: [Export query results to file](#)

Immunisation History Audit

Part 1 – Mother Vaccination

1. For list a), Pregnant women over who have not received Abrysvo in the last 12 months.
 - the QI lead should check on the Australian Immunisation Register (AIR) to see whether the pregnant women has received Abrysvo elsewhere, as it may also be offered where they are receiving their antenatal care.
 - **If not**, and they are over 28 weeks' gestation they should be offered an appointment to receive this vaccine (it would be good practice to discuss/ check for dTPA and influenza vaccination at the same time).
 - **If yes**, they have had vaccination history recorded on AIR from another practice, update your clinical software to reflect immunisation history. Review if this is a regular patient or can be inactivated.

Part 2 – Baby Vaccination

To extract the data of babies who are eligible to receive Beyfortus, the 4 lists of patients list above are to be worked on simultaneously, and will require crosschecking between the lists.

List c) Babies born after 01/10/25,

2. List c) Babies born after 01/10/25,

Quality Improvement (QI) Plan-Do-Study-Act (PDSA)

QI activity focus / Objective		Increasing uptake of RSV Immunisation in pregnant women and babies	
QI activity lead/s		Practice nurse	
Start measure	Number of eligible babies immunised against RSV ____	End measure	Number of eligible babies immunised against RSV ____
	Number of pregnant women immunized against RSV ____		Number of pregnant women immunized against RSV ____
	Number of eligible children entering their second RSV season immunized against RSV ____		Number of eligible children entering their second RSV season immunized against RSV ____
Start date	June 2026	End date	September 2026

	<ul style="list-style-type: none"> ○ Check AIR and if no vaccinations given - Implement recall system to contact parents to book baby in for vaccination. <p>3. List d) is children who are particularly vulnerable entering their second RSV season and should be offered Beyfortus regardless of having received it the previous year or maternal vaccination.</p> <ul style="list-style-type: none"> ○ All of the patients appearing on this list should be contacted and offered an appointment to discuss. <p>4. This process will be repeated fortnightly/ monthly during the RSV season to capture new pregnancies/ new babies/ new children entering the eligibility categories.</p>
<p>Step 3: STUDY</p> <p>What did you observe?</p>	<p>Results:</p> <p>The number of eligible pregnant patients vaccinated with Abrysvo increased by <u> # </u> in the 2025 RSV season.</p> <p>The number of eligible babies immunised with Beyfortus increased by <u> # </u> in the 2025 RSV season.</p> <p>The number of eligible children entering their second season of RSV immunised with Beyfortus increased by <u> # </u> in the 2025 RSV season.</p> <p>Questions to reflect and lessons learned</p> <ul style="list-style-type: none"> ○ Are there any barriers noted in offering these immunisations? ○ Do staff need any further education? ○ Is any patient education material required? ○ Has there been any patient feedback on these measures? ○ Has there been any feedback from staff on these measure? ○ Have there been any barriers to this activity? ○ Has anything worked particularly well in running this activity?
<p>Step 4: ACT</p> <p>Will you adopt, adapt or abandon this change?</p>	<p>Adopt: This process will be reviewed and then repeated yearly as per the government's advice on RSV immunisation.</p>

Quality Improvement (QI) Plan-Do-Study-Act (PDSA)

QI activity focus / Objective		Increasing uptake of RSV Immunisation in pregnant women and babies	
QI activity lead/s		Practice nurse	
Start measure	Number of eligible babies immunised against RSV ____	End measure	Number of eligible babies immunised against RSV ____
	Number of pregnant women immunized against RSV ____		Number of pregnant women immunized against RSV ____
	Number of eligible children entering their second RSV season immunized against RSV ____		Number of eligible children entering their second RSV season immunized against RSV ____
Start date	June 2026	End date	September 2026

Any other information?

Examples: notes, screenshots, graphs, context information, resources, Brainstorming

RSV Links

- RSV Maternal and Infant Immunisation Recall and Reminder Guide: [RSV-Maternal-and-Infant-Immunisation-Guide-250324.pdf](#)
- Maternal RSV Vaccination information: [2026 WA Respiratory Syncytial Virus \(RSV\) Infant and Maternal Immunisation Program](#)





Links Best Practice Knowledge base

- [Bp Premier Support Guidance - Database Search](#)
- [Best Practice Knowledge base - Searching the Database](#)
 - [Best Practice Knowledge base - Supplied Database Queries](#)
 - [Useful Database Queries to Run](#)



RSV PDSA.xlsx

Try using this spreadsheet to help cross check data:

Title	SQL File (double click icon to open & then save)	SQL Text
List a) Pregnant women over who have not received Abrysvo in the last 12 months.	 List a) Pregnant women over who have not received Abrysvo in the last 12 months.	<pre>SELECT * FROM BPS_Patients WHERE StatusText = 'Active' AND NOT InternalID IN (SELECT InternalID FROM Immunisations WHERE VaccinID = 214 AND RecordStatus = 1) AND InternalID IN (SELECT InternalID FROM ObsGynDetail WHERE NominalLMP >= DateAdd(Day, -300, GetDate()) AND RecordStatus = 1) ORDER BY surname, firstname</pre>
List b) Women who have had a pregnancy recorded within the last year and have received Abrysvo within the last 12 months.	 List b) Women who have had a pregnancy recorded within the last year and have received Abrysvo within the last 12 months.	<pre>SELECT * FROM BPS_Patients WHERE StatusText = 'Active' AND InternalID IN (SELECT InternalID FROM Immunisations WHERE VaccinID = 214 AND RecordStatus = 1) AND InternalID IN (SELECT InternalID FROM ObsGynDetail WHERE NominalLMP >= DateAdd(Day, -300, GetDate()) AND RecordStatus = 1) ORDER BY surname, firstname</pre>
List c) Babies born after 1/10/2024	 List c) Babies born after 1.10.2024.sql	<pre>SELECT * FROM BPS_Patients WHERE StatusText = 'Active' AND DOB >= '10/01/2024' ORDER BY surname, firstname</pre>
List d) Children born after 01/10/2023 who are Aboriginal or Torres Strait Islander or have an eligible Medical Risk Condition (MRC).	 List d) Children born after 01.10.2023	<pre>SELECT * FROM BPS_Patients WHERE StatusText = 'Active' AND DOB >= '10/01/2023' AND ((Ethnicity = 'Aboriginal' OR Ethnicity = 'Torres Strait Islander' OR Ethnicity = 'Aboriginal/Torres Strait Islander') OR InternalID IN (SELECT InternalID FROM PastHistory WHERE ItemCode IN (521, 4739, 3691, 3814, 3826, 12026, 3765, 5892, 5599, 2175, 2174, 463, 478, 485, 7845, 449, 6075, 453, 456, 473, 490, 6205, 443, 2418, 6813, 464, 6218, 5602, 112, 445, 444, 8290, 2442, 329, 7957, 5438, 446, 3745, 447, 4682, 2294, 2290, 5038, 448, 2291, 12011, 462, 2223, 8027, 2292, 5443, 7066, 11927, 451, 457, 458, 459, 460, 469, 454, 472, 474, 476, 477, 480, 481, 482, 486, 487, 488, 489, 11911, 491, 492, 494, 5451, 9391, 7751, 483, 470, 471, 8261, 2506, 6835, 6830, 6819, 6814, 3221, 2427, 4707, 6796, 4720, 4723, 452, 5600, 2177, 2176, 5018, 6654, 6003, 5480, 6812, 5491, 5009, 12010, 11767, 6076, 1440, 8028, 4803, 4807, 3212, 5402, 6541, 7011, 4828, 1269, 4961, 8291, 6426, 4841, 8293, 2178, 4845, 6542, 4894, 2224, 5401, 484, 13146, 5571, 3218, 2479, 465, 3215, 7005, 5604, 2173, 2179, 4907, 2293, 4599, 8292, 2222, 5054, 2225, 2226, 5595, 3219, 2273, 5875, 2287, 7252, 2269, 5601, 5603, 5608, 5607, 2257, 4936, 6115, 2289, 5061, 2295, 120, 475, 2350, 4673, 5573, 2444, 4956, 6811, 2499, 3220, 2432, 4963, 3209, 4972, 2447, 4976, 4979, 2449, 6167, 4984, 2453, 2455, 6769, 6676, 2264, 2459, 2460, 3746, 4112, 3162, 5139, 3211, 3214, 3208, 3217, 2463, 3935, 466, 455, 3229, 467, 2465, 5074, 5481, 5403, 2471, 5095, 2473, 2474, 1727, 1545, 1547, 1548, 1549, 1551, 1552, 2931, 13347, 2947, 7046, 702, 836) AND RecordStatus = 1) ORDER BY surname, firstname</pre>

Quality Improvement (QI) Plan-Do-Study-Act (PDSA)

QI activity focus / Objective		Increasing uptake of RSV Immunisation in pregnant women and babies	
QI activity lead/s		Practice nurse	
Start measure	Number of eligible babies immunised against RSV ____	End measure	Number of eligible babies immunised against RSV ____
	Number of pregnant women immunized against RSV ____		Number of pregnant women immunized against RSV ____
	Number of eligible children entering their second RSV season immunized against RSV ____		Number of eligible children entering their second RSV season immunized against RSV ____
Start date	June 2026	End date	September 2026


Any other information?

Examples: notes, screenshots, graphs, context information, resources, Brainstorming

Questions, Links and information:

- What is a smart goal?: [SMART Goals Cheat Sheet](#)
- How to document a PDSA? [Guide to documenting a QI activity as a PDSA](#)
- Does this need to be documented in a PDSA or can it be captured in a QI log? [Identifying and undertaking QI activities using PDSAs](#)

QI Quintuple Aims for health care improvement:



10 PIP QI Measures.

1. diabetes with HbA1c result
2. smoking status
3. weight classification
4. 65+ and Influenza Immunisation
5. Diabetes and Influenza Immunisation
6. COPD and Influenza Immunisation
7. alcohol consumption status
8. risk factors enable CVD assessment
9. cervical screening
10. diabetes & blood pressure

Building blocks

